Published in Nat Rev Nephrol on March 12, 2013
Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet (2012) 56.72
Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet (2012) 41.47
Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet (2012) 26.95
Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010. Lancet (2012) 11.32
Healthy life expectancy for 187 countries, 1990-2010: a systematic analysis for the Global Burden Disease Study 2010. Lancet (2012) 8.22
Age-specific and sex-specific mortality in 187 countries, 1970-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet (2012) 7.62
GBD 2010: understanding disease, injury, and risk. Lancet (2012) 2.34
Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet (2010) 6.23
Blood pressure-lowering treatment based on cardiovascular risk: a meta-analysis of individual patient data. Lancet (2014) 6.23
Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: a systematic review and meta-analysis of randomised controlled trials. Lancet (2009) 4.73
Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J Am Soc Nephrol (2009) 4.43
Effects of antiplatelet therapy on mortality and cardiovascular and bleeding outcomes in persons with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med (2012) 3.78
Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials. BMJ (2008) 3.35
Meta-analysis: erythropoiesis-stimulating agents in patients with chronic kidney disease. Ann Intern Med (2010) 2.97
Coffee, decaffeinated coffee, and tea consumption in relation to incident type 2 diabetes mellitus: a systematic review with meta-analysis. Arch Intern Med (2009) 2.79
Follow-up of blood-pressure lowering and glucose control in type 2 diabetes. N Engl J Med (2014) 2.64
Do men and women respond differently to blood pressure-lowering treatment? Results of prospectively designed overviews of randomized trials. Eur Heart J (2008) 2.41
HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database Syst Rev (2014) 2.35
HMG CoA reductase inhibitors (statins) for dialysis patients. Cochrane Database Syst Rev (2013) 2.21
Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)--a randomized placebo-controlled trial. Am Heart J (2013) 2.12
The relative and combined ability of high-sensitivity cardiac troponin T and N-terminal pro-B-type natriuretic peptide to predict cardiovascular events and death in patients with type 2 diabetes. Diabetes Care (2013) 2.07
Is low birth weight an antecedent of CKD in later life? A systematic review of observational studies. Am J Kidney Dis (2009) 1.94
Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes: New results from the ADVANCE trial. Diabetes Care (2009) 1.89
Systematic review: sodium bicarbonate treatment regimens for the prevention of contrast-induced nephropathy. Ann Intern Med (2009) 1.86
Effects of fibrates in kidney disease: a systematic review and meta-analysis. J Am Coll Cardiol (2012) 1.84
Aspirin is beneficial in hypertensive patients with chronic kidney disease: a post-hoc subgroup analysis of a randomized controlled trial. J Am Coll Cardiol (2010) 1.74
Effect of statin therapy on cardiovascular and renal outcomes in patients with chronic kidney disease: a systematic review and meta-analysis. Eur Heart J (2013) 1.74
Lowering blood pressure reduces renal events in type 2 diabetes. J Am Soc Nephrol (2009) 1.68
Circulating bone morphogenetic protein-7 and transforming growth factor-β1 are better predictors of renal end points in patients with type 2 diabetes mellitus. Kidney Int (2012) 1.63
HMG CoA reductase inhibitors (statins) for kidney transplant recipients. Cochrane Database Syst Rev (2014) 1.52
HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database Syst Rev (2009) 1.52
Preoperative estimates of glomerular filtration rate as predictors of outcome after surgery: a systematic review and meta-analysis. Anesthesiology (2013) 1.51
Cardiovascular risk management in chronic kidney disease in general practice (the AusHEART study). Nephrol Dial Transplant (2011) 1.50
Effects of uric acid-lowering therapy on renal outcomes: a systematic review and meta-analysis. Nephrol Dial Transplant (2013) 1.47
Long-term cancer risk of immunosuppressive regimens after kidney transplantation. J Am Soc Nephrol (2010) 1.45
Effects of intensive blood pressure lowering on the progression of chronic kidney disease: a systematic review and meta-analysis. CMAJ (2013) 1.43
Trials in kidney disease--time to EVOLVE. N Engl J Med (2012) 1.42
The effects of blood pressure reduction and of different blood pressure-lowering regimens on major cardiovascular events according to baseline blood pressure: meta-analysis of randomized trials. J Hypertens (2011) 1.41
Sharing Data from Cardiovascular Clinical Trials - A Proposal. N Engl J Med (2016) 1.34
Effects of a fixed combination of perindopril and indapamide in patients with type 2 diabetes and chronic kidney disease. Eur Heart J (2010) 1.34
Corticosteroid therapy in IgA nephropathy. J Am Soc Nephrol (2012) 1.30
Isolated low levels of high-density lipoprotein cholesterol are associated with an increased risk of coronary heart disease: an individual participant data meta-analysis of 23 studies in the Asia-Pacific region. Circulation (2011) 1.27
Linagliptin lowers albuminuria on top of recommended standard treatment in patients with type 2 diabetes and renal dysfunction. Diabetes Care (2013) 1.26
Proteinuria and stroke: a meta-analysis of cohort studies. Am J Kidney Dis (2008) 1.22
Omega 3 Fatty acids and cardiovascular outcomes: systematic review and meta-analysis. Circ Cardiovasc Qual Outcomes (2012) 1.21
Effects of beta-adrenergic antagonists in patients with chronic kidney disease: a systematic review and meta-analysis. J Am Coll Cardiol (2011) 1.16
Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: a systematic review and meta-analysis. PLoS Med (2012) 1.12
Antiplatelet agents for chronic kidney disease. Cochrane Database Syst Rev (2013) 1.08
Intensities of renal replacement therapy in acute kidney injury: a systematic review and meta-analysis. Clin J Am Soc Nephrol (2010) 1.07
Blood pressure is a major risk factor for renal death: an analysis of 560 352 participants from the Asia-Pacific region. Hypertension (2009) 1.03
Antioxidants for chronic kidney disease. Cochrane Database Syst Rev (2012) 1.02
Survival of elderly dialysis patients is predicted by both patient and practice characteristics. Nephrol Dial Transplant (2012) 1.01
Industry-sponsored clinical trials in emerging markets: time to review the terms of engagement. JAMA (2013) 1.01
Efficacy and safety of canagliflozin in patients with type 2 diabetes and stage 3 nephropathy. Am J Nephrol (2014) 1.01
Prediction of kidney-related outcomes in patients with type 2 diabetes. Am J Kidney Dis (2012) 0.99
Antiplatelet therapy to prevent hemodialysis vascular access failure: systematic review and meta-analysis. Am J Kidney Dis (2012) 0.96
Effects of SGLT2 inhibitors on cardiovascular outcomes. Diab Vasc Dis Res (2012) 0.95
HMG CoA reductase inhibitors (statins) for dialysis patients. Cochrane Database Syst Rev (2009) 0.95
Socioeconomic disadvantage and kidney disease in the United States, Australia, and Thailand. Am J Public Health (2008) 0.94
Resting heart rate and the risk of microvascular complications in patients with type 2 diabetes mellitus. J Am Heart Assoc (2012) 0.92
Renal and cardio-protective effects of direct renin inhibition: a systematic literature review. J Hypertens (2009) 0.91
Challenges of conducting a trial of uric-acid-lowering therapy in CKD. Nat Rev Nephrol (2011) 0.90
Angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and combined therapy in patients with micro- and macroalbuminuria and other cardiovascular risk factors: a systematic review of randomized controlled trials. Nephrol Dial Transplant (2011) 0.90
Antihypertensive agents for preventing diabetic kidney disease. Cochrane Database Syst Rev (2012) 0.89
A challenge to chronic kidney disease in Asia: The report of the second Asian Forum of Chronic Kidney Disease Initiative. Nephrology (Carlton) (2010) 0.87
Effects of salt substitute on pulse wave analysis among individuals at high cardiovascular risk in rural China: a randomized controlled trial. Hypertens Res (2009) 0.87
Efficacy and safety of routine blood pressure lowering in older patients with diabetes: results from the ADVANCE trial. J Hypertens (2010) 0.86
The CARI guidelines. Dialysis adequacy (HD) guidelines. Nephrology (Carlton) (2005) 0.85
HMG CoA reductase inhibitors (statins) for kidney transplant recipients. Cochrane Database Syst Rev (2009) 0.85
Prospective evaluation of aortic stenosis in end-stage kidney disease: a more fulminant process? Nephrol Dial Transplant (2010) 0.84
Co-payments for health care: what is their real cost? Aust Health Rev (2015) 0.83
Intensive glycemic control and renal outcome. Contrib Nephrol (2011) 0.83
New insights from ADVANCE. J Hypertens Suppl (2007) 0.83
Cyclosporine withdrawal improves long-term graft survival in renal transplantation. Transplantation (2009) 0.82
Tripterygium preparations for the treatment of CKD: a systematic review and meta-analysis. Am J Kidney Dis (2013) 0.81
Anticoagulant therapies for the prevention of intravascular catheters malfunction in patients undergoing haemodialysis: systematic review and meta-analysis of randomized, controlled trials. Nephrol Dial Transplant (2013) 0.81
Outcomes of extended-hours hemodialysis performed predominantly at home. Am J Kidney Dis (2012) 0.81
Phosphate in early chronic kidney disease: associations with clinical outcomes and a target to reduce cardiovascular risk. Nephrology (Carlton) (2012) 0.80
Interventions for erythropoietin-resistant anaemia in dialysis patients. Cochrane Database Syst Rev (2013) 0.80
Diuretics: a modern day treatment option? Nephrology (Carlton) (2006) 0.79
The risk of cancer in people with diabetes and chronic kidney disease. Nephrol Dial Transplant (2012) 0.79
Managing cardiovascular risk in people with chronic kidney disease: a review of the evidence from randomized controlled trials. Ther Adv Chronic Dis (2011) 0.79
HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Sao Paulo Med J (2015) 0.78
mTOR inhibition in autosomal-dominant polycystic kidney disease (ADPKD): the question remains open. Nephrol Dial Transplant (2012) 0.78
ADVANCE: breaking new ground in type 2 diabetes. J Hypertens Suppl (2006) 0.78
HMG CoA reductase inhibitors (statins) for dialysis patients. Cochrane Database Syst Rev (2009) 0.78
Clinical characteristics of IgA nephropathy associated with low complement 4 levels. Ren Fail (2014) 0.77
Design and participant baseline characteristics of 'A Clinical Trial of IntensiVE Dialysis': the ACTIVE Dialysis Study. Nephrology (Carlton) (2015) 0.77
Mortality in dialysis patients may not be associated with ESA dose: a 2-year prospective observational study. BMC Nephrol (2012) 0.77
ACEIs for cardiovascular risk reduction--have we taken our eye off the ball? Aust Fam Physician (2013) 0.76
Cardiovascular disease in patients with chronic kidney disease. Nephrology (Carlton) (2014) 0.76
Glomerular filtration rate and the risk of stroke. BMJ (2010) 0.76
Interventions for lowering plasma homocysteine levels in kidney transplant recipients. Cochrane Database Syst Rev (2015) 0.76
A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med (2016) 0.75
Blood pressure management in diabetes: a path forward? J Hypertens (2011) 0.75
The effect of pentoxifylline on oxidative stress in chronic kidney disease patients with erythropoiesis-stimulating agent hyporesponsiveness: Sub-study of the HERO trial. Redox Rep (2015) 0.75
Authors' reply to Ladapo and Ogedegbe. BMJ (2014) 0.75
The authors reply:. Kidney Int (2013) 0.75
Anticoagulants and antiplatelet agents for preventing central venous haemodialysis catheter malfunction in patients with end-stage kidney disease. Cochrane Database Syst Rev (2016) 0.75
Interventions for lowering plasma homocysteine levels in dialysis patients. Cochrane Database Syst Rev (2016) 0.75
Global kidney disease. Lancet (2013) 0.75
Hematuria in thin basement membrane nephropathy. Semin Nephrol (2005) 0.75
Optimal targets for blood pressure control in chronic kidney disease: the debate continues. Curr Opin Nephrol Hypertens (2014) 0.75
The rationale and design of the Beta-blocker to LOwer CArdiovascular Dialysis Events (BLOCADE) Feasibility Study. Nephrology (Carlton) (2015) 0.75
Side effects and tolerability of combination blood pressure lowering according to blood pressure levels: an analysis of the PROGRESS and ADVANCE trials. J Hypertens (2017) 0.75